We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04672980
Recruitment Status : Terminated (The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22. RTX-321 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared from circulation rapidly (w/in 10 min).)
First Posted : December 17, 2020
Last Update Posted : December 8, 2022
Sponsor:
Information provided by (Responsible Party):
Rubius Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an open-label, multicenter, multiple-ascending dose, FIH, Phase 1 study of RTX-321 for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or metastatic, unresectable, HPV 16+ cancers.

Condition or disease Intervention/treatment Phase
Cervical Cancer Head and Neck Cancer Anal Cancer Drug: RTX-321 Phase 1

Detailed Description:
This is a Phase 1, open label, multicenter, multidose, first-in-human (FIH) dose escalation and expansion to determine the safety and tolerability, recommended phase 2 dose and pharmacology, and antitumor activity of RTX-321 in adult patients with persistent, recurrent, or metastatic, unresectable cervical cancer (squamous, adeno, or adenosquamous histology), HNSCC, or squamous cell cancer of the anal canal that is not amenable to curative therapy. Prior to study screening, all patients must be confirmed to be HLA-A*02:01 positive. Documentation of an HPV 16+ tumor is required at prescreening for patients with cervical cancer and HNSCC. RTX-321 is a cellular therapy that expresses 4-1BBL, IL-12, and HPV-16 Antigen with the goal of harnessing the innate and adaptive immune systems for the treatment of cancer. The study will include a monotherapy dose escalation phase followed by an expansion phase.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of RTX-321 for the Treatment of Patients With Advanced Malignancies Associated With Human Papillomavirus-16 Infection
Actual Study Start Date : April 8, 2021
Actual Primary Completion Date : November 30, 2022
Actual Study Completion Date : November 30, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: RTX-321 Dose Escalation
Phase 1: RTX-321 administered intravenously on Day 1 of each cycle monotherapy dose escalation
 Drug: RTX-321
RTX-321 monotherapy
Experimental: RTX-321 Dose Expansion
Phase 1: RTX-321 administered intravenously on Day 1 of each cycle.
 Drug: RTX-321
RTX-321 monotherapy


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety Assessment by rate of Adverse Events: [ Time Frame: up to 30 months ]
    Measured by incidence of Treatment Emergent Adverse Events (TEAEs)

  2. Dose limiting toxicities (DLTs) of RTX-321: [ Time Frame: up to 30 months ]
    As determined by incidence and severity of adverse events (AEs)


Secondary Outcome Measures :
  1. Pharmacodynamics (PD) of RTX-321: [ Time Frame: up to 30 months ]
    As measured by the changes in number of CD8+ T-cells in peripheral blood using flow cytometry

  2. Pharmacokinetics (PK) of RTX-321: [ Time Frame: up to 30 months ]
    As measured by the detection of the number of RTX-321 cells using flow cytometry

  3. Anti-tumor activity of RTX-321 [ Time Frame: up to 30 months ]
    measured by duration of response (DoR)

  4. Anti-tumor activity of RTX-321 [ Time Frame: up to 30 months ]
    Measured by overall survival (OS)

  5. Anti-tumor activity of RTX-321 [ Time Frame: up to 30 months ]
    Measured by progression free survival (PFS)

  6. Anti-tumor activity of RTX-321 [ Time Frame: up to 30 months ]
    Measured by overall response rate (ORR)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent obtained prior to study procedures Patients ≥18 years with an ECOG 0 or 1
  • Histologically confirmed diagnosis by the local laboratory of persistent, recurrent, or metastatic, unresectable cervical cancer (squamous, adeno, or adenosquamous histology), HNSCC, or squamous cell cancer of the anal canal that is not amenable to curative therapy.
  • All patients must have experienced disease progression following platinum-based or mitomycin C-based chemotherapy administered in the persistent, recurrent, or metastatic setting.
  • All patients with programmed death-ligand 1 (PD-L1) positive cervical cancer and those with HNSCC must have received or have been determined to be ineligible for immunotherapy with a PD-1 or PD-L1 inhibitor.
  • All patients with cervical cancer will have received or have been determined to be ineligible for bevacizumab.
  • Confirmation of HLA-A*02:01 positive status by central testing.
  • In patients with cervical cancer or HNSCC, confirmation of HPV 16 within the tumor either from historical pathology result (using an FDA-approved HPV testing method, patients with cervical cancer only) or based on central laboratory analysis of a tumor sample. Patients with anal cancer will not be required to have prospective determination of HPV 16 positive status prior to enrollment.
  • Disease must be measurable per Response Evaluation Criteria
  • The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior therapy, before initiation of study treatment.

  • Adequate Organ Function as Defined by the protocol:

    • AST and ALT ≤3 × the upper limit of normal (ULN)
    • Except in documented cases of Gilbert syndrome, total bilirubin ≤1.5 × ULN
    • Serum albumin ≥2.5 g/dL
    • Serum or plasma creatinine ≤1.5 × ULN and/or glomerular filtration rate ≥50 mL/min/1.73 calculated by the Cockcroft-Gault formula
    • Absolute neutrophil count ≥1 × 103/μL, without myeloid growth factor support for ≥1 week
    • Platelet count ≥100 × 103/μL, without platelet transfusion for ≥1 week
    • Hemoglobin ≥9 g/dL, without red blood cell transfusion for ≥2 weeks

Exclusion Criteria:

  • Patient has central nervous system (CNS) involvement. If the patient fulfills the following 3 criteria, she/he is eligible for the trial after consultation with the Sponsor Medical Monitor.

    • Completed prior therapy for CNS metastases (radiation and/or surgery)
    • CNS tumor(s) is clinically stable at the time of enrollment
    • Patient does not require corticosteroid or antiepileptic therapy for management of CNS metastases
  • Known hypersensitivity to any component of study treatment or excipients.
  • Positive antibody screen using institution's standard type and screen test.
  • Clinically significant, active and uncontrolled infection, including human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04672980


Locations
Layout table for location information
United States, Alabama
University of Alabama
Birmingham, Alabama, United States, 35249
United States, California
The Angeles Clinic & Research Institute
Los Angeles, California, United States, 90025
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
United States, Missouri
Washington University
Saint Louis, Missouri, United States, 63110
United States, New York
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, United States, 10016
United States, Oklahoma
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United States, Virginia
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Sponsors and Collaborators
Rubius Therapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Rubius Therapeutics
ClinicalTrials.gov Identifier: NCT04672980    
Other Study ID Numbers: RTX-321-01
First Posted: December 17, 2020    Key Record Dates
Last Update Posted: December 8, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anus Neoplasms
Neoplasms by Site
Neoplasms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
 Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases